Advisory Research Inc Vertex Pharmaceuticals Inc Transaction History

Advisory Research Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $2,705 - $2,899	8 Added 0.74%	1,092 $379,000
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $340,831 - $381,470	1,084 New	1,084 $381,000
Q4 2018 Feb 13, 2019	SELL	$151.91 - $192.21 $173,785 - $219,888	-1,144 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$167.73 - $192.74 $191,883 - $220,494	1,144 New	1,144 $220,000
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $218,580 - $254,940	-1,500 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $65,946 - $77,051	-435 Reduced 22.48%	1,500 $244,000
Q4 2017 Feb 08, 2018	SELL	$137.28 - $155.55 $43,792 - $49,620	-319 Reduced 14.15%	1,935 $290,000
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $333,885 - $365,688	2,254	2,254 $343,000

1,717

226M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.